{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:46:30Z","timestamp":1790934390370,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,3,24]],"date-time":"2009-03-24T00:00:00Z","timestamp":1237852800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1007\/s10549-009-0352-y","type":"journal-article","created":{"date-parts":[[2009,3,23]],"date-time":"2009-03-23T09:50:23Z","timestamp":1237801823000},"page":"81-87","source":"Crossref","is-referenced-by-count":82,"title":["Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study"],"prefix":"10.1007","volume":"118","author":[{"given":"Georgiana K.","family":"Ellis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry G.","family":"Bone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowan","family":"Chlebowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devchand","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Spadafora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,3,24]]},"reference":[{"key":"352_CR1","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1200\/JCO.2006.08.8054","volume":"25","author":"M Kaufmann","year":"2007","unstructured":"Kaufmann M, Jonat W, Hilfrich J et al (2007) Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol 25:2664\u20132670. doi: 10.1200\/JCO.2006.08.8054","journal-title":"J Clin Oncol"},{"key":"352_CR2","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1001\/jama.295.23.joc60075","volume":"295","author":"SR Land","year":"2006","unstructured":"Land SR, Wickerham DL, Costantino JP et al (2006) Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 295:2742\u20132751. doi: 10.1001\/jama.295.23.joc60075","journal-title":"JAMA"},{"key":"352_CR3","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1056\/NEJMoa052258","volume":"353","author":"B Thurlimann","year":"2005","unstructured":"Thurlimann B, Keshaviah A, Coates AS et al (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747\u20132757. doi: 10.1056\/NEJMoa052258","journal-title":"N Engl J Med"},{"key":"352_CR4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(05)74803-0","volume":"365","author":"A Howell","year":"2005","unstructured":"Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5\u00a0years\u2019 adjuvant treatment for breast cancer. Lancet 365:60\u201362. doi: 10.1016\/S0140-6736(05)74803-0","journal-title":"Lancet"},{"key":"352_CR5","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1470-2045(06)70767-7","volume":"7","author":"TAT Group","year":"2006","unstructured":"Group TAT (2006) Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7:633\u2013643. doi: 10.1016\/S1470-2045(06)70767-7","journal-title":"Lancet Oncol"},{"key":"352_CR6","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","volume":"350","author":"RC Coombes","year":"2004","unstructured":"Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081\u20131092. doi: 10.1056\/NEJMoa040331","journal-title":"N Engl J Med"},{"key":"352_CR7","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.2005.09.121","volume":"23","author":"EP Winer","year":"2005","unstructured":"Winer EP, Hudis C, Burstein HJ et al (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23:619\u2013629. doi: 10.1200\/JCO.2005.09.121","journal-title":"J Clin Oncol"},{"key":"352_CR8","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","volume":"21","author":"BE Hillner","year":"2003","unstructured":"Hillner BE, Ingle JN, Chlebowski RT et al (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042\u20134057. doi: 10.1200\/JCO.2003.08.017","journal-title":"J Clin Oncol"},{"key":"352_CR9","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","volume":"25","author":"AS Coates","year":"2007","unstructured":"Coates AS, Keshaviah A, Thurlimann B et al (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1\u201398. J Clin Oncol 25:486\u2013492. doi: 10.1200\/JCO.2006.08.8617","journal-title":"J Clin Oncol"},{"key":"352_CR10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1470-2045(07)70003-7","volume":"8","author":"RE Coleman","year":"2007","unstructured":"Coleman RE, Banks LM, Girgis SI et al (2007) Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 8:119\u2013127. doi: 10.1016\/S1470-2045(07)70003-7","journal-title":"Lancet Oncol"},{"key":"352_CR11","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.2007.11.0726","volume":"26","author":"R Eastell","year":"2008","unstructured":"Eastell R, Adams JE, Coleman RE et al (2008) Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 26:1051\u20131057. doi: 10.1200\/JCO.2007.11.0726","journal-title":"J Clin Oncol"},{"key":"352_CR12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jsbmb.2005.04.009","volume":"95","author":"R Eastell","year":"2005","unstructured":"Eastell R, Hannon R (2005) Long-term effects of aromatase inhibitors on bone. Steroid Biochem Mol Biol 95:151\u2013154. doi: 10.1016\/j.jsbmb.2005.04.009","journal-title":"Steroid Biochem Mol Biol"},{"key":"352_CR13","first-page":"2874","volume":"26","author":"GK Ellis","year":"2008","unstructured":"Ellis GK, Bone HG, Chlebowski R et al (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for non-metastatic breast cancer. J Clin Oncol 26:2874\u20132882","journal-title":"J Clin Oncol"},{"key":"352_CR14","unstructured":"National Osteoporosis Foundation (2008) Clinician\u2019s guide to prevention and treatment of osteoporosis. Available at http:\/\/www.nof.org\/professionals\/Clinicians_Guide.htm . Accessed 15 January 2009"},{"key":"352_CR15","volume-title":"Random coefficient models","author":"NT Longford","year":"1993","unstructured":"Longford NT (1993) Random coefficient models. Oxford University Press, Inc., New York"},{"key":"352_CR16","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/annonc\/mdn164","volume":"19","author":"P Hadji","year":"2008","unstructured":"Hadji P, Body JJ, Aapro MS et al (2008) Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 19:1407\u20131416. doi: 10.1093\/annonc\/mdn164","journal-title":"Ann Oncol"},{"key":"352_CR17","doi-asserted-by":"crossref","first-page":"544","DOI":"10.4158\/EP.9.6.544","volume":"9","author":"SF Hodgson","year":"2003","unstructured":"Hodgson SF, Watts NB, Bilezikian JP et al (2003) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 9:544\u2013564","journal-title":"Endocr Pract"},{"key":"352_CR18","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1210\/jc.2007-2814","volume":"93","author":"HG Bone","year":"2008","unstructured":"Bone HG, Bolognese MA, Yuen CK et al (2008) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 93:2149\u20132157. doi: 10.1210\/jc.2007-2814","journal-title":"J Clin Endocrinol Metab"},{"key":"352_CR19","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","volume":"24","author":"JP Brown","year":"2009","unstructured":"Brown JP, Prince RL, Deal C et al (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24:153\u2013161. doi: 10.1359\/jbmr.0809010","journal-title":"J Bone Miner Res"},{"key":"352_CR20","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","volume":"25","author":"A Brufsky","year":"2007","unstructured":"Brufsky A, Harker WG, Beck JT et al (2007) Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 25:829\u2013836. doi: 10.1200\/JCO.2005.05.3744","journal-title":"J Clin Oncol"},{"key":"352_CR21","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/cncr.23259","volume":"112","author":"NJ Bundred","year":"2008","unstructured":"Bundred NJ, Campbell ID, Davidson N et al (2008) Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer 112:1001\u20131010. doi: 10.1002\/cncr.23259","journal-title":"Cancer"},{"key":"352_CR22","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2005.02.7102","volume":"25","author":"MF Gnant","year":"2007","unstructured":"Gnant MF, Mlineritsch B, Luschin-Ebengreuth G et al (2007) Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 25:820\u2013828. doi: 10.1200\/JCO.2005.02.7102","journal-title":"J Clin Oncol"},{"key":"352_CR23","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1200\/JCO.2007.15.2967","volume":"26","author":"SL Greenspan","year":"2008","unstructured":"Greenspan SL, Brufsky A, Lembersky BC et al (2008) Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol 26:2644\u20132652. doi: 10.1200\/JCO.2007.15.2967","journal-title":"J Clin Oncol"},{"key":"352_CR24","doi-asserted-by":"crossref","unstructured":"Lester J, Dodwell D, Purohit O et al (2008) Use of monthly oral ibandronate to prevent anastrozole-induced bone loss during adjuvant treatment for breast cancer: two-year results from the ARIBON study [abstract 554]. J Clin Oncol 26:S554","DOI":"10.1200\/jco.2008.26.15_suppl.554"},{"issue":"suppl 1","key":"352_CR25","first-page":"S37","volume":"106","author":"C Poznak Van","year":"2007","unstructured":"Van Poznak C, Hannon R, Clack G (2007) The SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE) study: 12\u00a0month analysis. Breast Cancer Res and Treat 106(suppl 1):S37 abs 502","journal-title":"Breast Cancer Res and Treat"},{"key":"352_CR26","unstructured":"Cummings SR, McClung MR, Christiansen C et al (2008) A phase III study of the effects of denosumab on vertebral, nonvertebral, and hip fracture in women with osteoporosis: results from the FREEDOM trial [abstract 1286]. J Bone Miner Res 23:S80"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-009-0352-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-009-0352-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-009-0352-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T16:32:16Z","timestamp":1559233936000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-009-0352-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,24]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["352"],"URL":"https:\/\/doi.org\/10.1007\/s10549-009-0352-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,24]]}}}